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Abstract
In concurrent chemoradiotherapy, chemotherapeutic agents are administered during the
course of radiotherapy to enhance the primary tumor control. However, that often comes at
the expense of increased risk of normal-tissue complications. The additional biological damage
is mainly attributed to two mechanisms of action, which are the independent cytotoxic activ-
ity of chemotherapeutic agents and their interactive cooperation with radiation. The goal of
this study is to develop a mathematical framework to obtain drug and radiation administration
schedules that maximize the therapeutic gain for concurrent chemoradiotherapy. In particular,
we analyze the impact of incorporating these two mechanisms into the radiation fractionation
problem. Considering each mechanism individually, we first derive closed-form expressions for
the optimal radiation fractionation regimen and the corresponding drug administration sched-
ule. We next study the case in which both mechanisms are simultaneously present and develop
a dynamic programming framework to determine optimal treatment regimens. Results show
that those chemotherapeutic agents that interact with radiation may change optimal radiation
fractionation regimens. Moreover, administration of chemotherapeutic agents possessing both
mechanisms may give rise to optimal non-stationary fractionation schemes.
Keywords: Chemoradiotherapy, fractionation, biologically-effective dose, mathematical opti-
mization, dynamic programming
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1 Introduction
In radiotherapy, high-energy radiation is used to eradicate cancer cells by damaging their
deoxyribonucleic-acid (DNA) molecule. As the radiation beam passes through the patient it
damages both cancerous and normal cells along its path. The majority of radiotherapy treat-
ment plans are divided into daily treatment fractions and delivered over the course of one
to several weeks. This allows late-responding normal tissues to partially repair the radiation-
induced damage between treatment fractions. Moreover, it is suggested that the core of large
tumors may be oxygen deprived, so-called hypoxic, and thus more radio-resistant (Coleman,
1988; Kumar, 2000). Fractionated radiotherapy allows for reoxygenation of hypoxic tumor re-
gions during the course of the treatment, thereby making the tumor cells more susceptible to
radiation. Radio-sensitivity of a cell also depends on the phase of the cell cycle. Cells in their
S phase and G2-M phases are relatively more radio-resistant and radio-sensitive, respectively
(Terasima and Tolmach, 1961). Hence, fractionated radiotherapy benefits from redistribution
of surviving tumor cells in radio-sensitive cell-cycle phases. Finally, tumor and normal-tissue
repopulation during the course of the treatment is an important factor considered in fraction-
ated radiotherapy (see Withers (1975); Pajonk et al. (2010) for 4 R’s of fractionation, which are
repair, reoxygenation, redistribution, and repopulation). Therefore, the choice of fractionation
regimen, that is, the number of fractions used and the radiation dose delivered per fraction, can
play an important role in the treatment outcome. The biologically-effective dose (BED) model
is a commonly-used concept in clinical practice to measure and compare the biological damage
caused by different radiation fractionation regimens (see Fowler (1989, 2010); Hall and Giaccia
(2006)).
For many advanced-stage cancers, radiotherapy alone is insufficient to successfully eradi-
cate all tumor cells without severely damaging the surrounding normal tissues. In particu-
lar, for inoperable tumors, chemoradiotherapy (CRT) is the standard of care, in which one
or several chemotherapeutic agents are administered along with radiation to enhance tumor
cell kill. CRT treatment regimens are classified into neoadjuvant, concurrent, or adjuvant
depending on whether the chemotherapeutic agents are administered before, during, or after
the course of radiotherapy, respectively. The rationale for combining chemotherapy with ra-
diation in concurrent CRT may vary across different chemotherapeutic agents. Nevertheless,
Steel and Peckham (1979) proposed a conceptual framework to summarize possible ways of
combining the two modalities. In the following, we discuss an adaptation of this framework
suggested by Bernier and Bentzen (2003):
• spatial cooperation referring to a non-interactive cooperation in which radiation eradicates
the primary local tumor while chemotherapy targets the systemic disease and sub-clinical
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metastases
• additivity referring to added locoregional effects of the two modalities assuming no inter-
action between the cytotoxic activity of radiation and chemotherapeutic agents
• radio-sensitization referring to enhancement of radiation-induced cell kill due to chemother-
apeutic agents
• radio-protection referring to an antagonistic effect of chemotherapeutic agents on radiation-
induced damage.
Many clinical trials have demonstrated lower incidence rate of distant metastases in patients
treated with concurrent CRT compared to radiotherapy alone, which verifies the spatial cooper-
ation mechanism (Seiwert et al., 2007b). Moreover, it has been clinically shown that concurrent
CRT leads to a better local tumor control for several treatment sites compared to radiotherapy
alone (see, e.g., Seiwert et al. (2007b)). However, that often comes at the expense of increased
risk of normal-tissue complications (see, e.g., Parashar et al. (2011)). The enhancement of the
local tumor control is explained by the additivity and radio-sensitization mechanisms. More
specifically, the additive cytotoxic activity of chemotherapeutic agents is attributed to the drug-
induced DNA damage. For instance, Cisplatin is a platinum-based anti-cancer drug, which is
commonly used in concurrent CRT. It is suggested that Cisplatin distorts the DNA molecule
structure via introducing inter- and intra-strand cross-links leading to cell death (Huang et al.,
1995). Radio-sensitization is the mechanism through which the radiation-induced damage is
enhanced, which also has been referred to as supra-additivity or synergism in the literature.
Several mechanisms of action have been suggested for radio-sensitization including (i) direct
enhancement of initial radiation damage by incorporating drugs into the DNA, (ii) inhibition
of post-irradiation DNA-damage repair by blocking the corresponding pathways, (iii) accumu-
lation of cells in a radio-sensitive phase (G2 and M phases) or elimination of cells that are in
a radio-resistant phase (S phase), (iv) elimination of hypoxic cells, and (v) inhibition of tu-
mor repopulation (see Nishimura (2004); Seiwert et al. (2007b) for a detailed discussion). For
instance, radio-sensitization properties of 5-Fluorouracil (5-FU), a chemotherapeutic agent typ-
ically administered intravenously during radiotherapy, are primarily ascribed to mechanisms
(i)–(iii) (Seiwert et al., 2007b). Finally, the radio-protection mechanism ideally allows larger
radiation doses by selectively protecting the normal tissue against radiation. An example of a
chemotherapeutic agent with radio-protection properties is Amifostine, which is used to reduce
the incidence or severity of normal-tissue toxicity without compromising the local tumor control
(Brizel et al., 2000; Movsas et al., 2005); however, the radiation protection benefit of Amifostine
remains disputable in clinical trials (Buentzel et al., 2006). This paper focuses on concurrent
CRT regimens that are founded upon additivity and radio-sensitization mechanisms.
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The additivity and radio-sensitization mechanisms are rarely specific to tumor cells and may
also increase the biological damage to normal tissues (Nishimura, 2004). Therefore, a ther-
apeutic benefit is only achieved if enhancement of the primary tumor control outweighs the
additional normal-tissue toxicity. Moreover, the interaction between the drug and radiation,
particularly the radio-sensitization mechanism, is time and dose dependent. Hence, combining
the best available radiotherapy fractionation regimen with the most promising chemotherapy
drug-administration schedule may not necessarily optimize the treatment outcome for concur-
rent CRT (Bernier and Bentzen, 2003). To maximize the therapeutic gain for concurrent CRT
one has to simultaneously consider the radiation and drug administration schedules. This sug-
gests the possible role of mathematical optimization in assisting with the design of promising
CRT treatment regimens using dose-response models. However, many of the treatment regimens
currently used in concurrent CRT have been solely initiated from phase I and II clinical trials
rather than the underlying biological principles (Wilson et al., 2006). Although mathemati-
cal optimization has been vastly employed to determine fractionation regimens in radiotherapy
(see, e.g., Bortfeld et al. (2013); Wein et al. (2000); Yang and Xing (2005)) and drug adminis-
tration schedules in chemotherapy (see Shi et al. (2011) for a complete review), the application
of mathematical optimization techniques to CRT fractionation decision has not been adequately
explored. To the best of our knowledge, Jones and Dale (2005) is the only study that promotes
the use of mathematical modeling and optimization for CRT fractionation decision. The goal
of this paper is to take an initial step toward developing a mathematical framework to study
the fractionation problem in concurrent CRT. The aim, in particular, is to identify changes in
optimal fractionation regimens that result from adding chemotherapeutic agents to the radia-
tion treatment. To achieve this goal, we extend the radiation BED model to account for the
additivity and radio-sensitization mechanisms. Using the extended BED model we then formu-
late the CRT fractionation problem as a non-linear programming model. We derive closed-form
expressions for the optimal fractionation regimens for special cases in which either additive or
radio-sensitization effect is relevant. Furthermore, we develop a dynamic programming (DP)
framework to study optimal fractionation regimens for chemotherapeutic agents that possess
both mechanisms (see Bertsekas (2005) for a complete review of DP).
The remainder of this paper is organized as follows: In Section 2, we introduce the BED
model and discuss how it is used to make fractionation decision in radiotherapy. We then
consider the extension of the BED model to CRT and formulate the CRT fractionation problem.
In Section 3, we derive closed-form solutions to the CRT fractionation problem considering the
additive and radio-sensitization effects individually. We also develop a DP algorithm to solve the
CRT fractionation problem when both effects are simultaneously present. In Section 4, we apply
the results derived in Section 3 to a photon and proton treatment plan and study the impact
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of introducing chemotherapeutic agents on the optimal fractionation regimens. In Section 5,
we present some insights into the CRT fractionation decision provided by the obtained results
and discuss limitations of the study and future research directions. Finally, in Section 6, we
summarize and conclude the paper.
2 Fractionation decision
In this section we review the optimal fractionation regimens for radiotherapy, discuss the frac-
tionation decision in the context of chemoradiotherapy, and formulate the corresponding frac-
tionation problem.
2.1 Radiotherapy
It is widely accepted that the logarithm of the surviving fraction of irradiated cells follows
a linear-quadratic fit (Hall and Giaccia, 2006). Originally motivated by this observation, the
notion of BED is defined and used in clinical practice to quantify and compare the biological
effect of radiation fractionation regimens. The BED associated with a fractionation regimen
with n treatment fractions, where a radiation dose of di Gray (Gy) is administered at fraction
i = 1 . . . , n, is
BED =
n∑
i=1
di
(
1 +
di
[α/β]
)
,
where [α/β] (measured in Gy) is a tissue-specific parameter. Several clinical studies have as-
sociated different BED values, independent of the number of fractions n and radiation doses
di (i = 1, . . . , n), with tumor control probability (TCP) and normal-tissue complication proba-
bility (NTCP) and have suggested BED tolerance values for different normal tissues to avoid
radiation toxicity (Marks et al., 2010). In order to achieve the maximum TCP in many treat-
ment sites (e.g., lung cancer), it is clinically desirable to determine fractionation regimens that
deliver the maximum BED in the target region while ensuring that the BED in the surrounding
normal tissue does not exceed the corresponding tolerance value. Several studies have used math-
ematical optimization to determine optimal fractionation regimens to achieve this. Mizuta et al.
(2012) studied the dependence of the optimal fractionation regimen on the BED parameters of
the target [α/β]T and normal tissue [α/β]N assuming each receives a uniform dose of di and
δdi (δ ≥ 0 is so-called sparing factor) at fraction i = 1, . . . , n, respectively. In particular, they
showed that if [α/β]N > δ [α/β]T, then a stationary hypo-fractionation regimen is optimal,
that is, using as few fractions as possible with equal doses per fraction; otherwise, a stationary
standard fractionation regimen is preferable, that is, using the maximum number of fractions al-
lowed with equal doses per fraction. Lastly, using extended BED models Bortfeld et al. (2013)
5
and Yang and Xing (2005) incorporated the tumor repopulation effect into the fractionation
decision.
The assumption of the uniformity of the normal-tissue dose distribution is unrealistic in
clinical practice. Radiotherapy plans often deliver a uniform dose to the target region while
depositing a heterogeneous dose distribution in the normal tissue, which, in turn, leads to
a heterogeneous BED distribution in the normal tissue. The normal-tissue tolerance against
radiation depends on the arrangement of the functional subunits (FSUs) in the organ. FSU is
the largest unit of cells capable of being regenerated from a single cell without any functionality
loss (Withers et al., 1988). In parallel organs, such as lung, FSUs are arranged in parallel and
function relatively independently. As a result, parallel structures are able to tolerate a relatively
large radiation dose if it is limited to small sub volumes. On the contrary, in serial organs, such
as spinal cord, FSUs are arranged in series and the integrity of each FSU is critical to the
organ function. Hence, large radiation is harmful to serial organs even if it is delivered to a
small sub volume. In radiotherapy treatment planning, this effect is typically accounted for
by using the generalized mean of the dose distribution (Niemierko, 1999). In particular, for a
“perfectly” parallel and serial organ the generalized mean reduces to the average and maximum
of the dose distribution, respectively. Using the generalized mean of the BED distribution,
Keller et al. (2013) and Unkelbach et al. (2013) have independently extended the fractionation
decision studied in Mizuta et al. (2012) to allow for a heterogeneous dose distribution in the
normal tissue. In particular, they have identified ranges of the ratio [α/β]N / [α/β]T for which
a hypo- or standard fractionation regimen is optimal. In this paper, we extend the framework
developed in Unkelbach et al. (2013) to study the CRT fractionation decision.
2.2 Chemoradiotherapy
Chemotherapeutic agents administered in concurrent CRT cause additional biological damage
in the target and normal tissue owing to the additivity and radio-sensitization mechanisms
discussed in Section 1. Several dose-response models have been proposed in the literature to
study this additional biological damage. We first review those models and then formulate the
CRT fractionation problem assuming a dose-response model motivated by those studies.
2.2.1 CRT dose-response model
Steel and Peckham introduced the isobologram analysis to study the interaction between chemother-
apeutic agents and radiation (Steel, 1979; Steel and Peckham, 1979). More specifically, an
isobologram is generated by plotting different drug and radiation dose levels that lead to an
identical cytotoxic effect, which are called isoeffect curves. Two isoeffect curves corresponding
to two different modes of interaction between the drug and radiation are generated. These
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curves form the-so-called envelope of additivity. Next, the true isoeffect curve is empirically
obtained and contrasted against the envelope. Depending on whether this curve lies above,
within, or below the envelope, the drug and radiation interaction is classified as sub-additive
(antagonistic), additive, or supra-additive (synergistic), respectively. Note that the isobologram
analysis may only be used to classify the type of interaction between a given chemotherapeutic
agent and radiation, and it does not provide an explicit dose-response relationship for concurrent
CRT. However, to incorporate the additivity and radio-sensitization mechanisms in the CRT
fractionation decision, one needs to employ a quantitative model that associates different drug
and radiation dose levels with biological damage. One possible approach is to extend the radia-
tion BED model to account for the two mechanisms. The earliest extension in the literature is
the introduction of the dose modifying factor (DMF), also known as the sensitizer enhancement
ratio (SER), to account for the additional biological damage caused by the chemotherapeutic
agent. It is defined as the ratio of radiation doses with and without the chemotherapeutic
agent that lead to the same biological effect (Wigg, 2001). However, the DMF does not distin-
guish between additivity and radio-sensitization mechanisms and does not consider the drug’s
concentration. Other studies have used an extended BED model that only accommodates the
additivity mechanism (Jones and Dale, 2005; Vogelius et al., 2011a,b). In particular, they in-
troduce the notion of chemotherapy-equivalent radiation dose (CERD), which is an additional
radiation BED measured in fractional doses of 2 Gy, to account for the cytotoxic activity of the
drug. Although CERD may account for the additivity mechanism, it is intrinsically incapable
of modeling the radio-sensitization effect.
Clonogenic assay is an in-vitro technique to determine the impact of a single or a combina-
tion of agents on the survival and proliferation of cells (Hall and Giaccia, 2006). The graphical
representation of this analysis, which illustrates the relationship between the fraction of sur-
viving cells and the drug’s concentration or radiation dose, is called a survival curve. Survival
curves for many malignant and normal cell lines grown in culture and exposed to radiation
or chemotherapeutic agents have been determined. In particular, survival curves of irradiated
cell lines, regardless of their species of origin, follow a linear-quadratic (LQ) fit on a logarith-
mic scale (Hall and Giaccia, 2006). Several clonogenic-assay studies address the additivity and
radio-sensitization mechanisms through studying the changes observed in the LQ survival curve
if irradiated cell lines are also exposed to chemotherapeutic agents. In the following, we highlight
some of those studies to motivate an extension to the BED model for concurrent CRT.
Additivity mechanism The additivity mechanism leads to an increase in cell kill due to
the cytotoxic activity of the chemotherapeutic agent. The underlying assumption for the ad-
ditivity mechanism is the lack of any interactive cooperation between the drug and radiation.
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Thus, individual survival curves of radiation and chemotherapeutic agents can be employed to
characterize the survival curve for the combined case. Several clonogenic-assay studies suggest
that survival curves of cell lines that are only exposed to chemotherapeutic agents have an expo-
nential form in terms of the drug’s concentration (see, e.g., Berenbaum (1969); Eichholtz-Wirth
(1980); Giocanti et al. (1993); Skipper et al. (1964)). Hence, to account for the additivity mech-
anism, one may add a linear term with respect to the drug’s concentration to the exponent of
the LQ model (see Appendix A).
Radio-sensitization mechanism This mechanism enhances the radiation-induced cell
kill. Therefore, radio-sensitization may change the shape of the LQ survival curve. In particular,
several clonogenic-assay studies suggest that this mechanism increases the initial slope of the LQ
model. More specifically, they report an increase in the linear term of the LQ model without an
appreciable change in the quadratic term (see, e.g., Franken et al. (2001, 2011); Dai et al. (2013);
Joiner and van der Kogel (2009); Chavaudra et al. (1989); Miller et al. (1992)). Moreover, the
extent of this increase depends on the drug’s concentration. Therefore, to accommodate the
radio-sensitization mechanism, one may add a multiplicative term with respect to the radiation
dose and the drug’s concentration to the exponent of the LQ model (see Appendix A).
Extending BED to concurrent CRT The radiation BED model is originally motivated
by the LQ survival curve. Chemotherapeutic agents change the LQ survival curve due to their
additivity and radio-sensitization mechanisms. Hence, to extend the BED model to concurrent
CRT we assume that the additional biological damage due to additivity and radio-sensitization is
accounted for via adding a linear and multiplicative term to the BED model, respectively. More
specifically, consider a treatment regimen in which a drug concentration of ci and a radiation
dose of di are administered at treatment fraction i = 1, . . . , n. We define a function B : R
2 → R
as
B (di, ci) = di
(
1 +
di
[α/β]
)
+ θci + ξcidi, (1)
where θ and ξ are tissue-specific parameters associated with additive and radio-sensitization
effects, respectively. We then use B to measure the total biological damage caused in the tissue
due to radiation and drug administration at fraction i = 1, . . . , n. In order to calibrate the
effect of the additivity and radio-sensitization mechanisms against radiation, the parameters
θ and ξ are given in units of Gy per drug unit and the inverse of drug unit, respectively.
Analogous to the case of BED for radiation alone, it is then assumed that a given value of
extended BED, independent of the number of fractions n and fractional radiation and drug
doses (ci, di) (i = 1, . . . , n), is associated with a certain biological effect.
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2.2.2 Formulation of the CRT fractionation problem
We next consider the fractionation decision for concurrent CRT to determine a radiation frac-
tionation regimen along with the drug administration schedule to maximize the BED received
by the target while ensuring the BED delivered to the normal tissue does not exceed the cor-
responding tolerance. At each treatment fraction, the BED in the target and normal tissue is
measured using, respectively, functions BT and BN with tissue-specific parameters. To formulate
the CRT fractionation problem, we adopt the common approach, used in all studies discussed
in Section 2.1 and in particular Unkelbach et al. (2013), that prior to the fractionation decision,
the radiation treatment plan and the associated dose distribution are determined and given.
Moreover, we assume that this given treatment plan delivers a uniform dose to the target and
a heterogeneous dose distribution to the normal tissue. Therefore, the spatial dose distribution
in the target and normal tissue is fixed; however, the dose per fraction may be scaled up or
down as desired. Let V represent the set of all voxels in the normal tissue. The spatial dose
distribution delivered by the given radiation treatment plan can then be characterized as follows:
the target receives a uniform radiation dose of di at fraction i = 1, . . . , n, and voxel v ∈ V in
the normal tissue receives a radiation dose of δvdi, where δv ≥ 0 is the sparing factor of voxel
v. It is assumed that δv (v ∈ V ) does not change during the course of the treatment. Let n
represent an upper bound on the total number of treatment fractions allowed, which is enforced
due to logistical reasons or to avoid undesirable consequences of prolonging the treatment such
as tumor repopulation. The fractionation problem can then be formulated in terms of decision
variables of radiation dose di and drug concentration ci at fraction i = 1, . . . , n as follows:
max
n∑
i=1
BT (di, ci)
subject to (M)
1
|V |
∑
v∈V
n∑
i=1
BN (δvdi, ci) ≤ b¯ (2)
ci ≤ c¯ i = 1, . . . , n (3)
di, ci ≥ 0 i = 1, . . . , n. (4)
The objective function evaluates the cumulative BED delivered to the target over all treatment
fractions. The constraint in (2) ensures that the mean of the BED distribution in the normal
tissue does not exceed the specified threshold. This constraint is derived assuming that the
normal tissue has a parallel organ structure. If the normal tissue has a serial structure, then
(2) must be changed to limit the maximum of the BED distribution delivered to normal-tissue
voxels. Note that BN is an increasing function with respect to δv (v ∈ V ). Hence, the maxi-
mum of the BED distribution over all voxels v ∈ V corresponds to the voxel with the largest
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sparing factor. Therefore, in order to account for a serial normal tissue, the set of voxels V in
(2) is replaced with a single voxel with the largest sparing factor. Furthermore, in Appendix
B we discuss an approximation problem that allows for the application of the developed frame-
work to general organ structures. Constraints in (3) limit the drug’s concentration beyond c¯ to
prohibit concentration levels that lead to intolerable distant toxicities. More specifically, most
chemotherapeutic agents, in addition to locoregional toxicity in the dose-limiting normal tissue,
may have side effects such as nausea, fatigue, and diarrhea. Moreover, they can cause distant
toxicity, such as bone marrow suppression, nephrotoxicity (toxicity in kidneys), and ototoxicity
(hearing loss), among others (see, e.g., Seiwert et al. (2007a,b)). Limiting the drug’s concentra-
tion reduces the risk of drug-induced distant toxicity. Lastly, the set of constraints in (4) ensure
nonnegativity of the radiation dose and the drug’s concentration at each fraction.
In the next section, we develop solution methods to solve (M) and discuss the structure of
optimal fractionation regimens. To develop the solution method, we first consider special cases
in which additivity and radio-sensitization mechanisms are considered individually, and derive
closed-form expressions for the optimal treatment regimens. We then develop a DP algorithm
to solve the case in which both mechanisms are relevant.
3 Solution method
To study the optimal regimens to (M), we discuss the following four cases:
(i) radiotherapy alone
(ii) CRT with only the additivity mechanism
(iii) CRT with only the radio-sensitization mechanism
(iv) CRT with additivity and radio-sensitization mechanisms.
We start with presenting the following lemma on the mean of the optimal BED distribution
delivered to the normal tissue:
Lemma 3.1. For any optimal regimen (d∗i , c
∗
i ) (i = 1, . . . , n), the mean of the normal-tissue
BED distribution assumes its upper-bound value, that is,
1
|V |
∑
v∈V
n∑
i=1
BN (δvd
∗
i , c
∗
i ) = b¯
Proof. BT and BN are increasing functions of di and ci for i = 1, . . . , n. Therefore, if for a given
solution to (M), the constraint on the mean of the BED distribution is not binding, one may
increase di for some i to obtain a larger objective value until this constraint becomes binding.
Lemma 3.1 states that any optimal regimen to (M) yields a normal-tissue BED distribution
with the maximum mean allowed. Using Lemma 3.1 we can substitute the quadratic term
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∑n
i=1 d
2
i in BT and rewrite the objective function of (M) as follows:
n∑
i=1
BT (di, ci) =
1
δ2
[α/β]N
[α/β]T
b¯+
(
1−
1
δeff
[α/β]N
[α/β]T
) n∑
i=1
di
+
(
θT
θN
−
1
δ2
[α/β]N
[α/β]T
)
θN
n∑
i=1
ci +
(
ξT
ξN
−
1
δeff
[α/β]N
[α/β]T
)
ξN
n∑
i=1
cidi, (5)
in which δ¯ and δ2 are, respectively, the first and second moments of the sparing factors associated
with normal-tissue voxels and δeff is
δeff ≡ δ2/δ¯.
Using the new expression for the objective function of (M) in (5) as well as Lemma 3.1, we derive
closed-form solutions to (M) for cases (i)–(iii). The solution methods developed in this section
are also applicable to the approximation problem discussed in Appendix B, which accommodates
treatment sites in which the normal tissue does not necessarily have a parallel or serial organ
structure.
3.1 Radiotherapy alone
In the absence of chemotherapeutic agents, we have ci = 0 (i = 1, . . . , n). Hence, (5) reduces to
n∑
i=1
BT (di, 0) =
1
δ2
[α/β]N
[α/β]T
b¯+
(
1−
1
δeff
[α/β]N
[α/β]T
) n∑
i=1
di. (6)
Unkelbach et al. (2013) used (6) to show that the optimal solution is a stationary fractiona-
tion regimen that uses either the minimum or maximum number of fractions allowed, that is,
hypo-fractionation or standard fractionation, respectively (see also Mizuta et al. (2012) for the
mathematical result on the existence of optimal stationary regimens). We briefly derive this
result for later use. Using Lemma 3.1 and considering only stationary solutions, we determine
the optimal total radiation dose to be
n∑
i=1
di =
−1 +
√
1 + 4δeff b¯/nδ¯ [α/β]N
2δeff/n [α/β]N
. (7)
The expression in (7) is increasing in the number of fractions n. Therefore, depending on the
coefficient sign for the sum of radiation dose in (6), which we denote by
∆r = 1−
1
δeff
[α/β]N
[α/β]T
,
we determine the optimal number of fractions. More specifically, if ∆r ≥ 0, then the optimal
regimen uses the maximum number of fractions allowed (standard fractionation regimen); oth-
erwise, the use of the minimum number of fractions is optimal (hypo-fractionation regimen).
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Therefore, Unkelbach et al. (2013) introduced the following condition to determine whether a
standard fractionation regimen should be used:
[α/β]N ≤ δeff [α/β]T . (8)
If (8) is false, then a hypo-fractionation regimen is optimal.
3.2 CRT with additivity mechanism
Several cytotoxic agents, such as Temozolomide, are suggested to only have an additive effect
(Chalmers et al., 2009). This corresponds to the chemotherapeutic agent exhibiting insignificant
or no radio-sensitization. In other words, ξ = 0 in (1) for both the target and normal tissue. To
derive the optimal solution to (M), we consider two possible scenarios concerning whether the
chemotherapeutic agent can solely deposit a BED of b¯ or larger in the normal tissue, which is
summarized by
BN
(
0, c¯
)
≥
b¯
n
. (9)
We determine the optimal solution to (M) under the assumption that the condition in (9) is
satisfied and then generalize the solution to the second scenario in which this condition is not
satisfied. Substituting ξT, ξN = 0 in (5), we obtain the following expression for the objective
function of (M):
n∑
i=1
BT (di, ci) =
1
δ2
[α/β]N
[α/β]T
b¯ +
(
1−
1
δeff
[α/β]N
[α/β]T
) n∑
i=1
di +
(
θT
θN
−
1
δ2
[α/β]N
[α/β]T
)
θN
n∑
i=1
ci. (10)
For any drug concentrations ci (i = 1, . . . , n), it is easy to see that the fractionation problem
reduces to the radiation-only case of Section 3.1, in which the upper bound on the average BED
in the normal tissue reduces to b¯ − θN
∑n
i=1 ci. It immediately follows that for CRT with only
the additivity mechanism, there is an optimal stationary radiation fractionation regimen. To
characterize this regimen, let b = θN
∑n
i=1 ci represent the total BED delivered to the normal
tissue by the chemotherapeutic agent. Considering only stationary radiation fractionation regi-
mens with a fixed number of fractions n and using Lemma 3.1, we determine the optimal total
radiation dose, denoted by Da =
∑n
i=1 di, as a function of b as follows:
Da (b;n) =
−1 +
√
1 + 4δeff
(
b¯− b
)
/nδ¯ [α/β]N
2δeff/n [α/β]N
. (11)
The expressions for the objective function of (M) in (10) and the optimal total radiation dose
in (11), lead to the following theorem that describes the optimal solution to (M) for CRT with
only the additivity mechanism:
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Theorem 3.1. Let
∆r = 1−
1
δeff
[α/β]N
[α/β]T
,
∆a =
θT
θN
−
1
δ2
[α/β]N
[α/β]T
,
̺a =
b¯
Da (0; 1)
,
ρ
a
= δ¯
[
2δeff
n [α/β]N
Da
(
b¯;n
)
+ 1
]
,
ρa = δ¯
[
2δeff
n [α/β]N
Da (0;n) + 1
]
, and
ba = b¯+
n [α/β]N
4δ2
(
δ¯2 − (∆r/∆a)
2
)
.
In the presence of only the additivity mechanism, that is, ξT = ξN = 0, the optimal treatment
regimen to (M) is:
optimal regimen :


RT-hypo ∆r ≤ 0,∆a ≤ 0,∆r/∆a ≤ ̺a
RT-std ∆r ≥ 0,∆a ≤ 0
RT-std ∆r ≥ 0,∆a ≥ 0,∆r/∆a ≥ ρa
CRT-std ∆r ≥ 0,∆a ≥ 0, ρa < ∆r/∆a < ρa
CT ∆r ≥ 0,∆a ≥ 0,∆r/∆a ≤ ρa
CT ∆r ≤ 0,∆a ≥ 0
CT ∆r ≤ 0,∆a ≤ 0,∆r/∆a > ̺a,
where CT, RT-hypo, RT-std, and CRT-std are abbreviated forms of chemotherapy, radiotherapy
using hypo-fractionation, radiotherapy using standard fractionation, and chemoradiotherapy us-
ing standard fractionation, respectively. Furthermore, CRT-std delivers an average BED of ba
and b¯− ba to the normal tissue via drug and radiation administration, respectively.
The proof is in Appendix C. Figure 1 illustrates optimal regimens for different values of ∆r
and ∆a as specified in Theorem 3.1. The following observations are made for optimal treatment
regimens associated with CRT with only the additivity mechanism:
1. If ∆r ≥ 0, we have [α/β]N ≤ δeff [α/β]T, and thus it is optimal to administer radiation
using standard fractionation. This fractionation decision is independent of the use of the
chemotherapeutic agent.
2. If ∆r ≥ 0 and ∆a < 0, it is optimal to use radiation alone without administering the
drug. In contrast, if ∆r ≤ 0 and ∆a > 0 it is optimal to use chemotherapy alone with no
radiotherapy.
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Figure 1: Schematic of optimal regimens for CRT with only the additivity mechanism. Dotted and hatched
regions illustrate whether standard or hypo-fractionated radiotherapy is optimal, respectively.
3. For the case where ∆r and ∆a have the same sign, the ratio ∆r/∆a determines whether
the chemotherapeutic agent should be used. Transitioning thresholds are specified by ρ
a
,
ρa, and ̺a.
4. If a standard radiation fractionation is used, then there is a range of ∆r/∆a, that is,(
ρ
a
, ρa
)
, within which radiation and chemotherapy are combined. In contrast, for a hypo-
fractionated radiation regimen it is never optimal to administer an additive chemother-
apeutic agent concurrently with radiation. This aspect is explained further in Section
5.
We next discuss optimal regimens when (9) is not satisfied. In other words, the drug alone
is not able to deliver a BED of b¯ or larger to the normal tissue. It is easy to see that those
cases in Theorem 3.1 that only use radiation, which are RT-std and RT-hypo, continue to be
optimal under the new condition. However, the remaining cases, which are CT and CRT-std,
need to be adjusted accordingly. In particular, for the case of drug administration only CT,
the chemotherapeutic agent can deliver a maximum BED of nBN
(
0, c¯
)
. Hence, in order to
have the normal-tissue BED constraint be binding (see Lemma 3.1), an additional average BED
of b¯ − nBN
(
0, c¯
)
is required to be delivered using hypo- or standard fractionation radiation
depending on the sign of ∆r. Finally, for the case of CRT-std, a BED of min
{
nBN
(
0, c¯
)
, ba
}
and b¯−min
{
nBN
(
0, c¯
)
, ba
}
are delivered using drug and radiation administration, respectively.
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3.3 CRT with radio-sensitization mechanism
Chemotherapeutic agents such as hypoxic-cell radio-sensitizers are primarily used to enhance
radiation-induced damage and do not exhibit independent cytotoxic activity. For such agents,
we assume θ = 0 for the target and normal tissue in (1). Substituting θT, θN = 0 in (5), the
objective function of (M) is
n∑
i=1
BT (di, ci) =
1
δ2
[α/β]N
[α/β]T
b¯+
(
1−
1
δeff
[α/β]N
[α/β]T
) n∑
i=1
di +
(
ξT
ξN
−
1
δeff
[α/β]N
[α/β]T
)
ξN
n∑
i=1
cidi.
(12)
To derive the optimal solution to (M) for the radio-sensitization mechanism, we first show the
existence of a stationary fractionation regimen.
Proposition 3.1. If θT, θN = 0, then there exists an optimal stationary fractionation regimen
to (M).
The proof is in Appendix D. Proposition 3.1 states that there exists an optimal regimen(
d∗i , c
∗
i
)
(i = 1, . . . , n) to (M) in which for all pairs of fractions i, i′ such that d∗i , d
∗
i′ > 0, we have
d∗i = d
∗
i′ and c
∗
i = c
∗
i′ . In order to characterize this stationary regimen, we set c1 = c2 = . . . =
cn = c in (M). Using Lemma 3.1 we see that the optimal total radiation dose, which we denote
by Ds =
∑n
i=1 di, as a function of the drug concentration c for a fixed number of treatment
fractions n is
Ds (c;n) =
− (1 + ξNc) +
√
(1 + ξNc)
2 + 4δeff b¯/nδ¯ [α/β]N
2δeff/n [α/β]N
. (13)
This leads to the following result on the optimal fractionation regimen to (M) for CRT with
only the radio-sensitization mechanism:
Theorem 3.2. Let
∆r = 1−
1
δeff
[α/β]N
[α/β]T
,
∆s =
ξT
ξN
−
1
δeff
[α/β]N
[α/β]T
,
̺s =
ξNc¯
Ds (0; 1) /Ds (c¯; 1)− 1
,
ρ
s
=
2δeff
n [α/β]N
Ds (c¯;n) + 1,
ρs =
2δeff
n [α/β]N
Ds (0;n) + 1, and
cs =
ρ2s − (∆r/∆s)
2
2ξN (∆r/∆s − 1)
.
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In the presence of only the radio-sensitization effect, that is, θT = θN = 0, the optimal regimen
to (M) is
optimal regimen :


RT-hypo c∗ = 0 ∆r ≤ 0,∆s ≤ 0,∆r/∆s ≤ ̺s
RT-hypo c∗ = c¯ ∆r ≤ 0,∆s ≤ 0,∆r/∆s > ̺s
RT-hypo c∗ = c¯ ∆r ≤ 0,∆s ≥ 0,∆r/∆s ≤ −ξNc¯
RT-std c∗ = c¯ ∆r ≤ 0,∆s ≥ 0,∆r/∆s > −ξNc¯
RT-std c∗ = c¯ ∆r ≥ 0,∆s ≥ 0,∆r/∆s < ρs
RT-std 0 < c∗ = cs < c¯ ∆r ≥ 0,∆s ≥ 0, ρs ≤ ∆r/∆s < ρs
RT-std c∗ = 0 ∆r ≥ 0,∆s ≥ 0,∆r/∆s ≥ ρs
RT-std c∗ = 0 ∆r ≥ 0,∆s ≤ 0.
The proof is in Appendix E. Figure 2 illustrates the results presented in Theorem 3.2 for
different values of ∆r and ∆s. We make the following observations regarding the impact of
radio-sensitizers on the optimal fractionation regimens:
1. Since it is assumed that there is not any independent cytotoxic activity associated with
the chemotherapeutic agent, radiation is always administered in the optimal treatment
regimen.
2. The optimal radiation fractionation regimen and drug concentration always depend on
the ratio ∆r/∆s except for the case of ∆r ≥ 0,∆s ≤ 0. The transitioning thresholds are
specified by ρ
s
, ρs, ̺s, and −ξNc¯.
3. For standard fractionation regimens, there is a range of ∆r/∆s, that is,
(
ρ
s
, ρs
)
, within
which an intermediate drug-concentration level is optimal. However, for hypo-fractionated
regimens, the drug is either not used at all or delivered at maximum concentration level.
4. The administration of radio-sensitizers may alter the fractionation decision in radiotherapy.
More specifically, there are scenarios (∆r ≤ 0,∆s ≥ 0) in which a hypo-fractionated
regimen is optimal if no radio-sensitizer is used; however, in the presence of the radio-
sensitizer, it is optimal to switch to a standard fractionation regimen. This aspect will be
further discussed in Section 5.
3.4 CRT with additivity and radio-sensitization mechanisms
Several chemotherapeutic agents such as Gemcitabine and Cisplatin are suggested to have radio-
sensitization properties as well as independent cytotoxic activity (Hall and Giaccia, 2006). For
those agents that exhibit both additivity and radio-sensitization mechanisms, using the definition
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Figure 2: Schematic of optimal regimens for CRT with only the radio-sensitization mechanism. Zero,
intermediate, and maximum drug-concentration level (DCL) correspond to c∗ = 0, 0 < c∗ < c¯, and c∗ = c¯,
respectively. Dotted and hatched regions illustrate whether standard or hypo-fractionated radiotherapy is
optimal, respectively.
of ∆r, ∆a, and ∆s, the objective function of (M) in (5) is
n∑
i=1
BT (di, ci) =
1
δ2
[α/β]N
[α/β]T
b¯+∆r
n∑
i=1
di +∆a
(
θN
n∑
i=1
ci
)
+∆s
(
ξN
n∑
i=1
cidi
)
.
To obtain optimal treatment regimens for this case, we start with the following special cases:
1. ∆r ≥ 0, ∆a < 0, and ∆s < 0: it is easy to see that the optimal drug concentration is
c∗i = 0 (i = 1, . . . , n) since ∆a < 0 and ∆s < 0 discourage any positive drug concentration.
Therefore, the problem reduces to radiotherapy alone. In particular, since ∆r ≥ 0, a
standard radiation fractionation scheme is optimal.
2. ∆r < 0, ∆a ≥ 0, and ∆s < 0: in this case, ∆r < 0 and ∆s < 0 discourage any positive
radiation dose. Thus, the optimal treatment regimen uses only chemotherapy, that is,
d∗i = 0 (i = 1, . . . , n). However, this is only the case if condition (9) is satisfied; otherwise,
d∗i > 0 for some i and thus the optimal regimen also involves radiotherapy.
In general, it may not be possible to derive closed-form expressions for the optimal treatment reg-
imens if both mechanisms are present. This is mainly because optimal stationary regimens may
not necessarily exist. In fact, the numerical example in Section 4 shows that chemotherapeutic
agents with both mechanisms may give rise to optimal non-stationary regimens. Therefore, we
develop a DP algorithm to obtain optimal fractionation regimens to (M). The stages of the DP
algorithm refer to treatment fractions i = 1, . . . , n. The control variables are the radiation dose
and drug concentration (di, ci) used at stage i (i = 1, 2, . . . , n). The state of the system at the
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beginning of stage i, denoted by xi, is the mean of the cumulative BED in the normal tissue.
Thus, the state dynamics is
xi+1 = xi +
1
|V |
∑
v∈V
BN (δvdi, ci) i = 1, . . . , n,
where xn+1 represents the state of the system at the end of the treatment. At each stage
i (i = 1, . . . , n) we consider an intermediate reward of BT (di, ci) measuring the BED delivered
to the target during that stage. To ensure that the solution satisfies the constraint in (2), we
also define a terminal reward function, denoted by Rn+1 (xn+1), as follows:
Rn+1 (xn+1) =


0 xn+1 ≤ b¯;
−∞ xn+1 > b¯.
Associated with stage i (i = 1, . . . , n) we define the cost-to-go function, denoted by Ji (xi), as
the maximum cumulative reward that can be attained in remaining treatment fractions i, . . . , n
when starting with state xi. We can then write the Bellman’s recursive equations as follows:
Ji (xi) = max
0≤ci≤c¯
di≥0
{
BT (di, ci) + Ji+1
(
xi +
1
|V |
∑
v∈V
BN (δvdi, ci)
)}
i = 1, . . . , n (14)
Jn+1 (xn+1) = Rn+1 (xn+1) . (15)
The Bellman’s equations can be solved using backward recursion. This requires a discretization
of the state variables xi (i = 1, . . . , n). In oder to increase the accuracy of the evaluation of Ji at
non-discretized xi values, a linear interpolation of appropriate discretized values is performed.
Our DP framework is used to find optimal solutions to (M) when both additivity and radio-
sensitization mechanisms are relevant.
4 Numerical examples
In this section we discuss how the results obtained in Section 3 can be applied to treatment plans
designed for individual patients. As a proof of principle, we use a photon and proton treatment
plan for a locally-advanced lung cancer case, which are extracted from Zhang et al. (2010). In
particular, we assume that the target receives a uniform dose while the normal lung, as the
dose-limiting normal tissue, receives a heterogeneous dose distribution. Dose-volume histogram
(DVH) curves for the normal lung, associated with the photon and proton plans, are illustrated
in Figure 3. Clearly, the proton plan allows for a better sparing of the normal lung. For each
DVH curve, the first and second moments of the sparing factors δv (v ∈ V ), which are input
parameters to the mathematical results in Section 3, are calculated. We then use the results in
Section 3 to determine the optimal fractionation regimens and drug administration schedules
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for these two radiotherapy plans. We use common BED parameters of [α/β]T = 10 Gy and
[α/β]N = 4 Gy for the target and normal lung, respectively. We let b¯ = 25 Gy as the upper
bound on the average normal-lung BED. We also set c¯ = 1 considering a normalized maximum
drug concentration. Moreover, we consider a maximum number of n = 30 treatment fractions.
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Figure 3: DVH curves of the fractional dose in the normal lung for the photon (solid) and proton (dashed)
treatment plans provided in Zhang et al. (2010), for a locally-advanced lung cancer case.
Radiotherapy Using equations from Unkelbach et al. (2013) to determine the first and sec-
ond moments of sparing factors from the DVH curves, we obtain δ¯ = 0.42, δ2 = 0.31 and
δeff = 0.74 for the photon plan and δ¯ = 0.32, δ2 = 0.25, and δeff = 0.78 for the proton plan.
We first consider the case of radiotherapy alone and calculate ∆r, which is 0.46 and 0.49 for
the photon and proton plan, respectively. Since ∆r ≥ 0, a stationary standard fractionation
regimen is optimal for both the photon and proton plans.
CRT with only the additivity mechanism According to Theorem 3.1, since ∆r ≥ 0,
in order to use the drug in the optimal regimen, condition ∆r/∆a ≤ ρa should be satisfied, which
yields ∆a ≥ 0.70 and ∆a ≥ 0.88 for the photon and proton plan, respectively. Therefore, the
optimal regimen uses the drug along with radiation if θT/θN ≥ 1.99 and θT/θN ≥ 2.48 for the
photon and proton plan, respectively. This suggests that, to use the chemotherapeutic agent with
the proton plan, the relative additive effect of the drug in the target versus normal lung (θT/θN)
should be 25% larger compared to the photon plan. The difference between the threshold values
is attributed to the better sparing of the normal lung achieved using the proton plan, rendering
the use of a systemic agent with a small relative additive effect unattractive. Furthermore,
the optimal treatment regimen uses only the chemotherapeutic agent if θT/θN ≥ 2.39 and
θT/θN ≥ 3.13 in case of the photon and proton plan, respectively. Thus, it is optimal to
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combine the photon and proton plan with chemotherapeutic agents only if the corresponding
relative additive effect lies within [1.99, 2.39] and [2.48, 3.13], respectively.
CRT with only the radio-sensitization mechanism We next investigate the impact
of radio-sensitizers on the optimal regimens for the two plans. According to Theorem 3.2,
since ∆r ≥ 0, in order to have a positive drug concentration in the optimal regimen, condition
∆r/∆s ≤ ρs should be satisfied, which yields ∆s ≥ 0.29 and ∆s ≥ 0.28, or equivalently ξT/ξN ≥
0.83 and ξT/ξN ≥ 0.79 for the photon and proton plan, respectively. Hence, the relative radio-
sensitization effect in the target versus normal lung (ξT/ξN) for the photon plan is required
to be 5% larger compared to the proton plan. The difference in the threshold values is due
to the larger radiation dose delivered by the photon plan in the normal lung. This, in turn,
increases the radio-sensitization activity and thus the radiation toxicity in the normal lung. In
contrast, a proton plan can achieve a better sparing of the normal lung, thereby reducing the
radio-sensitization activity.
CRT with additivity and radio-sensitization mechanisms Finally, we consider
the impact of chemotherapeutic agents with combined mechanisms on the optimal regimens.
We apply our DP algorithm discussed in Section 3 to the photon and proton treatment plans
for different values of θT, θN, ξT, ξN ≥ 0. More specifically, we solve instances of (M) where
θT, θN, ξT, and ξN assume values in {0.1, 0.15, . . . , 1} corresponding to scenarios in which the
relative importance of additivity and radio-sensitization effects in (1) varies from 10% to 100% of
the radiation BED. A discretization step of 0.05 was used for the state and control variables. An
important observation is that the inclusion of both effects may lead to non-stationary optimal
regimens. Figure 4 depicts an example of a non-stationary regimen for the photon plan with
∆a < 0 and ∆s > 0 indicating that the additive and radio-sensitization effect is unfavorable and
favorable, respectively. The optimal regimen uses the chemotherapeutic agent in only a subset
of treatment fractions with an escalated radiation dose in those fractions to benefit from the
radio-sensitization mechanism. Note that the model does not consider the sequence of fractions
used in the fractionation regimen, and thus the solutions are insensitive to the order according
to which the fractions are administered. This case is further discussed in Section 5. Figure 5
illustrates the optimal regimens for different parameter values obtained by the DP algorithm
for the photon treatment plan. One major difference of the schematic of optimal regimens for
the combined mechanisms from those of individual mechanisms is the lack of sharp boundaries
between sub regions. More specifically, except for the third quadrant (∆a < 0, ∆s < 0), where it
can be analytically shown that RT-std is the only optimal treatment regimen (see Section 3.4),
the boundaries are not exclusive. Therefore, the dominant treatment regimen within each sub
region is illustrated in Figure 5. In particular, in the first quadrant (∆a ≥ 0, ∆s ≥ 0), where
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both additive and radio-sensitization effects are favorable, stationary CRT regimens are the
dominant form of optimal treatment regimens. In the second quadrant (∆a < 0, ∆s ≥ 0), where
the additive effect is unfavorable, non-stationary CRT regimens are optimal. The example
in Figure 4 belongs to this quadrant. The optimal treatment regimen in the third quadrant
(∆a < 0, ∆s < 0) is radiotherapy only using a standard fractionation regimen, as discussed in
Section 3.4. Finally, in the fourth quadrant (∆a ≥ 0, ∆s < 0), where the radio-sensitization effect
is unfavorable, it might be still desirable to administer the chemotherapeutic agent sequentially
with radiation (rather than concurrently) to avoid the unfavorable radio-sensitization effect and
at the same time to benefit from the additive effect. This leads to the dominance of sequential
CRT (neoadjuvant or adjuvant) regimens in this quadrant.
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Figure 4: An example of non-stationary optimal treatment regimens (insensitive to the fraction sequence)
for the photon plan where ∆r > 0, ∆a < 0, and ∆s > 0, using θT = 0.3, θN = 0.65, ξT = 0.65, and ξN = 0.25
(DCL: drug-concentration level).
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Figure 5: Schematic of optimal regimens for CRT with additivity and radio-sensitization mechanisms
obtained by the DP algorithm for the photon plan with ∆r = 0.46.
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5 Discussion
In this section we comment on the CRT fractionation regimens provided by the model. In
particular, using the results discussed in Sections 3 and 4, we make the following observations:
Diminishing return in target BED leads to combined-modality treatments
For the case of radiotherapy alone, using equations (6) and (7) and substituting b¯ with variable
b, we can write the target BED as a function of average normal-tissue BED for a given number
of treatment fractions n as follows:
H (b;n) =
1
δ2
[α/β]N
[α/β]T
b+∆r
−1 +
√
1 + 4δeffb/nδ¯ [α/β]N
2δeff/n [α/β]N
.
In particular, H (·;n) characterizes the trade-off between the target BED and the average
normal-tissue BED. It is easy to verify that H (·;n) is a concave function if ∆r ≥ 0, and
convex otherwise (see Appendix F). Therefore, when standard fractionation regimen is optimal,
the concavity of the trade-off curve suggests a diminishing return in the target BED as one
allows for an increase in the average normal-tissue BED. This implies that the introduction of
a second modality such as chemotherapeutic agents with additivity mechanism, may lead to a
larger gain in the target BED rather than solely escalating the radiation dose. Thus, the dimin-
ishing return in the target BED explains the existence of CRT optimal regimens in Theorem
3.1 despite assuming no interactive cooperation between the drug and radiation.
Chemotherapeutic agents with additivity mechanism do not change opti-
mal radiation fractionation regimens According to Theorem 3.1, the condition for
optimality of hypo- and standard fractionation regimen is ∆r < 0 and ∆r ≥ 0, respectively.
These conditions are identical to those of the radiotherapy-alone case, which suggests that the
introduction of chemotherapeutic agents with only the additivity mechanism does not lead to
a change in the optimal radiation fractionation scheme. However, the relative additive effect in
the target versus the normal tissue (θT/θN) determines the extent to which the drug is used in
the optimal regimen. In particular, Figure 1 illustrates that if ∆r ≥ 0 and ∆a ≥ 0 (first quad-
rant), then as θT/θN and, in turn, ∆a increases, the optimal regimen transitions from RT-std
to CRT-std and from CRT-std to CT. Similarly, if ∆r < 0 and ∆a < 0 (third quadrant), then
as θT/θN and thus ∆a increases, the optimal regimen changes from RT-hypo to CT.
Radio-sensitizers may change optimal hypo-fractionated radiation regimens
In contrast to the additivity mechanism, the radio-sensitization mechanism may lead to a change
in the optimal radiation fractionation scheme. More specifically, if ∆r < 0, then in the absence
of radio-sensitizers, a hypo-fractionation radiation regimen is optimal. However, this is not nec-
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essarily the case if a radio-sensitizer is being introduced. Figure 2 shows that if ∆r < 0 and
∆s ≥ 0 (second quadrant), then the maximum drug concentration allowed is optimal. Moreover,
if the relative radio-sensitization effect in the target versus normal tissue (ξT/ξN) is sufficiently
large, then the optimal radiation scheme changes from hypofrcationation to standard fractiona-
tion. This change in the fractionation regimen is explained as follows: since the maximum drug
concentration is administered at each fraction i = 1, 2, . . . , n, then (1) can be rewritten as
B (di, c¯)
1 + ξc¯
= di
(
1 +
di
[α/β] (1 + ξc¯)
)
.
This suggests the use of condition (8) as discussed in Section 3.1 to determine the optimal
radiation fractionation regimen using an effective [α/β] ratio for the target and normal tissue,
which are [α/β]T (1 + ξTc¯) and [α/β]N (1 + ξNc¯), respectively. Thus, for the case of ∆r < 0 and
∆s ≥ 0, if
[α/β]N (1 + ξNc¯) ≤ δeff [α/β]T (1 + ξTc¯) ,
then a standard fractionation regimen is optimal; otherwise, a hypo-fractionation regimen is
optimal. In particular, if ξT is sufficiently larger than ξN (case of chemotherapeutic agents with
preferential radio-sensitization activity in the target versus normal tissue), then the effective
[α/β] ratio in the target is larger than that of the normal tissue, thereby tipping the scales
toward standard radiation fractionation regimen.
Concurrent CRT with both mechanisms may favor non-stationary fraction-
ation regimens The numerical example illustrated in Figure 4 presents a case for which a
non-stationary treatment regimen is optimal. To provide an explanation for the existence of op-
timal non-stationary regimens, we consider the additivity and radio-sensitization mechanisms in
this example independently: for the additivity mechanism, since ∆r ≥ 0 and ∆a < 0, Theorem
3.1 does not recommend the administration of the chemotherapeutic agent. On the other hand,
for the radio-sensitization mechanism, since ∆r ≥ 0 and ∆s ≥ 0, Theorem 3.2 shows that the
use of a standard radiation fractionation regimen along with a maximum drug concentration is
optimal. Hence, if both mechanisms are simultaneously considered, then the optimal regimen
uses the drug in only a subset of fractions with an escalated radiation dose in those fractions.
This example may represent the scenario in which the chemotherapeutic agent has relatively
high toxicity in the normal tissue (small θT/θN) and at the same time relatively strong radio-
sensitization effect in the target (large ξT/ξN). Therefore, for such chemotherapeutic agents,
the use of non-stationary treatment regimens may be optimal.
Decision on administration of chemotherapeutic agents depends on the spa-
tial dose distribution The numerical example in Section 4 compares the fractionation
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regimens for a photon and proton treatment plan. The difference between the two is attributed
to a better sparing of the normal lung achieved by the proton therapy and thus smaller val-
ues of sparing factors, δ¯ and δ2 (note that smaller sparing factors do not necessarily lead to a
smaller δeff). In particular, in order to use chemotherapeutic agents with only the additivity
mechanism along with the proton treatment, larger values of θT/θN are required compared to
the photon treatment. This is because administration of a systemic agent with the proton treat-
ment is not beneficial unless its relative additive effect (θT/θN) is sufficiently large. In other
words, chemotherapeutic agents that are used concomitantly with proton plans are expected to
have larger selectivity in their additivity mechanism. On the other hand, in order to use radio-
sensitizers along with proton treatments, smaller values of ξT/ξN are acceptable compared to
photon treatments. This is because photon treatments typically deliver low doses of radiation to
a large part of the lung, which is so-called low-dose bath (see the DVH curve of normal lung for
the photon plan in Figure 3). The radio-sensitization mechanism increases the normal-lung tox-
icity caused by the low-dose bath. In contrast, the proton treatment has a significantly smaller
low-dose bath, thereby reducing the radio-sensitization activity in the normal lung. Hence, it
may be still beneficial to administer radio-sensitizers with a smaller preferential effect (smaller
ξT/ξN) along with the proton treatment.
Limitations of the study and future research directions Although the mechanism
of action for chemotherapeutic agents are suggested to be mainly of the additivity and radio-
sensitization forms, the extent of these effects may vary across different chemotherapeutic agents
and patients. Hence, the quantification of these effects is challenging (Wheldon, 1988). More-
over, the validity of the BED model and its parameter estimate have been questioned (see, e.g.,
Brenner (2008); Kirkpatrick et al. (2008)). Therefore, the role of mathematical optimization
in CRT is not to recommend alternative clinical practice but to generate hypotheses that can
inspire the design of new clinical trials. This study presents an initial attempt at developing a
mathematical framework for hypothesis generation in CRT treatment planning. This framework
can be further extended to accommodate additional clinical considerations as follows:
• For the proof of concept, we used a linear and multiplicative term in (1) to model the
additivity and radio-sensitization mechanisms, respectively. As an extension to this work,
we plan to study the structure of optimal treatment regimens for generalized BED models
where these mechanisms are accounted for using functions of other forms in terms of the
drug’s concentration and radiation dose.
• The presented results are based on the assumption that the dose-response parameters can
be accurately estimated. However, there may be uncertainty associated with parameter
estimation or variation across different patients. Davison et al. (2011) studied the impact
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of the uncertainty in radio-sensitivity parameters on the optimal radiotherapy fractionation
regimens and cautioned against the resulting variability in tumor-cell kill. In particular,
they characterized optimal fractionation regimens with minimal risk of treatment failure
for different uncertainty levels of the LQ model parameters. Furthermore, it is suggested
that some tumor reoxygenation may occur after a few fractions, altering the tumor radio-
sensitivity during the course of the treatment (Carlson et al., 2006). Our framework can
be extended to account for these sources of parameter uncertainty.
• A major factor impacting the fractionation decision is tumor repopulation during the
course of the treatment, particularly in treatment sites with a fast proliferating rate such
as head-and-neck cancers. If unaccounted for, tumor repopulation may severely compro-
mise the treatment outcome (Withers et al. (1988)). Ramakrishnan (2013) has shown
that in contrast to exponential repopulation for which a stationary and finite radiation
fractionation regimen is optimal, the incorporation of accelerated repopulation may lead
to non-stationery optimal regimens. Although in our current framework the repopula-
tion effect has not been explicitly accounted for, the bound enforced on the maximum
number of treatment fractions limits this effect. Our framework can be extended to ex-
plicitly incorporate the impact of accelerated repopulation in the fractionation decision for
chemoradiotherapy.
• It is assumed in our current framework that the drug administered at each treatment frac-
tion does not carry over to subsequent fractions. This assumption has served as the basis
for formulating the set of constraints in (3). However, this may not be necessarily valid for
some chemotherapeutic agents. Therefore, our framework should be tailored for individual
chemotherapeutic agents by accommodating the specifics of the drug pharmacokinetics.
• Our current formulation considers the CRT fractionation decision for a given spatial dose
distribution. More specifically, it is assumed that the spatial aspect of the treatment plan
is already determined and only the temporal aspect is optimized. Hence, the optimal so-
lution to the CRT fractionation problem may only scale the spatial dose distribution up
or down. However, as previously discussed in Section 5, the radiation dose distribution in-
fluences the radio-sensitization effect. Therefore, fixing the spatial dose distribution limits
the therapeutic gain that might be achieved through optimizing the fractionation regi-
men. This has been rightfully pointed out in other studies (see, e.g., Bernier and Bentzen
(2003)) stating that concurrent CRT may change the desirable radiation dose distribution
with respect to the normal tissue and target volume. Spatio-temporal planning aims at
simultaneously optimizing for the spatial and temporal aspects of the treatment plan and
has been previously studied for radiotherapy (see, e.g., Kim et al. (2012)). We plan to
investigate the extension of spatio-temporal treatment planning to concurrent CRT.
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6 Conclusion
We developed a mathematical framework to study the impact of chemotherapeutic agents on
optimal fractionation regimens. We considered an extension of the BED model to incorpo-
rate two major mechanisms of action for chemotherapeutic agents, which are additivity and
radio-sensitization. We then derived closed-form solutions to the fractionation problem for each
individual mechanism, and developed a DP algorithm to solve the fractionation problem with
combined mechanisms. Results suggest that chemotherapeutic agents with only an additive ef-
fect do not change the optimal radiation fractionation regimens; however, radio-sensitizers may
change hypo-fractionation regimens to standard ones. Moreover, chemotherapeutic agents with
both effects may give rise to non-stationary regimens. Lastly, the spatial dose distribution may
impact the use of chemotherapeutic agents along with radiation treatments. The demonstrated
results motivate future research to extend this framework to spatio-temporal planning and to
account for additional clinical considerations related to tumor repopulation as well as the mech-
anism of action and pharmacokinetics of chemotherapeutic agents. Such framework may assist
clinicians with hypothesis generation to design novel CRT fractionation schemes that can be
tested in clinical trials.
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Appendices
A Extending the BED Model to Concurrent CRT
In this section, we motivate the extended BED model defined in Section 2.2.1 through an exten-
sion of the LQ model to describe in-vitro cell-survival assays in the presence of chemotherapeutic
agents. The radiation LQ model is
SRT(d) = e
−(αd+βd2),
where SRT denotes the fraction of cells surviving radiation dose d and α and β are cell-specific
parameters. In addition, in-vitro assay studies suggest an exponential cell-survival curve for the
chemotherapeutic agent as follows:
SCT(c) = e
−γc,
where SCT denotes the fraction of cells surviving drug concentration c and γ is a cell-specific
parameter. The unit of the parameter γ is chosen such that γc is a dimensionless quantity. A
non-interactive cooperation between the chemotherapeutic agent and radiation yields a survival
fraction of
SRT(d)SCT(c) = e
−(αd+βd2+γc)
if cells are exposed to radiation dose d and drug concentration c. Furthermore, in-vitro assay
experiments on radio-sensitization indicate an increase in the parameter α of the LQ survival
curve, where the extent of this increase is proportional to the drug’s concentration. Therefore,
assuming a linear increase in the parameter α, the additivity and radio-sensitization mechanisms
yield the following survival curve
SCRT(d, c) ≈ e
−((α+mc)d+βd2+γc)
≈ e−(αd+βd
2+mcd+γc),
where SCRT is the fraction of cells surviving exposure to radiation dose d and drug concentration
c. The unit of the parameter m is chosen such that mc is in units of 1/Gy. The definition of
the radiation BED model was originally motivated as the absolute value of the exponent of the
LQ model divided by the linear parameter α, that is, − logSRT(d)/α. Similarly, we assume an
extended BED model for concurrent CRT as follows:
− logSCRT(d, c)
α
= d
(
1 +
d
[α/β]
)
+
m
α
cd+
γ
α
c
= d
(
1 +
d
[α/β]
)
+ ξcd+ θc,
where [α/β], ξ, and θ are tissue-specific parameters.
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B Accounting for a general normal-tissue structure
Formulation (M) is developed for treatment sites in which the dose-limiting normal tissue has
a “perfectly” parallel or serial organ structure. Therefore, the solution methods discussed in
Sections 3.1–3.4 are only applicable to these two cases. In this section, we present an approximate
formulation that allows for the application of the developed solution methods to treatment sites
with a general normal-tissue structure. In order to account for other organ structures the
constraint in (2) needs to be extended to limit the generalized mean of the BED distribution
in the normal tissue. More specifically, let zv represent the BED deposited in voxel v ∈ V over
the course of the treatment, that is,
zv =
n∑
i=1
BN (δvdi, ci) . (B.1)
To account for a dose-limiting normal tissue with an organ structure other than parallel or serial,
the constraint in (2) needs to be substituted with a new constraint that limits the generalized
mean of the BED distribution as follows:(
1
|V |
∑
v∈V
zav
)1/a
≤ b¯, (B.2)
where a ≥ 1 is a tissue-specific parameter. The parameter a has been determined and reported
for different organs (Marks et al., 2010). This yields an extension to (M) in which the constraint
in (2) is replaced with (B.1)–(B.2). The two cases of parallel and serial organs that were
previously discussed correspond to a = 1 and a =∞, respectively, which represent the average
and maximum of the BED distribution as follows:(
1
|V |
∑
v∈V
zav
)1/a
=


1
|V |
∑
v∈V zv a = 1;
maxv∈V zv a =∞.
(B.3)
In order to apply our developed solution methods to the new formulation, we first use the method
introduced in Thieke et al. (2002) to approximate the generalized mean of the BED distribution
using the convex combination of the average and maximum values. More specifically,(
1
|V |
∑
v∈V
zav
)1/a
≈ λ
(
1
|V |
∑
v∈V
zv
)
+ (1− λ)
(
max
v∈V
zv
)
, (B.4)
where λ ∈ [0, 1] is the convex-combination coefficient chosen based on the a-parameter value
(see Thieke et al. (2002) for more details). Since zv (v ∈ V ) increases as δv increases, we have
argmaxv∈V zv = argmaxv∈V δv. Let δmax represent the maximum sparing factor over all voxels
v ∈ V . Substituting (B.4) in (B.2) and zv (v ∈ V ) from (B.1) yields an approximate constraint
on the generalized mean of the BED distribution as follows:
γ
(
1
|V |
∑
v∈V
n∑
i=1
BN (δvdi, ci)
)
+ (1− γ)
n∑
i=1
BN (δmaxdi, ci) ≤ b¯. (B.5)
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Hence, replacing the constraint (2) of formulation (M) with (B.5) yields an approximation
problem that allows for a general organ structure. In particular, it is easy to see that an
argument similar to Lemma 3.1 applies to (B.5) requiring it to be binding at optimality. Thus,
the expression in (5) for the objective function of (M) is also applicable to the approximation
problem via substituting δ2 with λδ2 + (1− λ) δ2max and δ¯ with λδ¯ + (1− λ) δmax. This, in
turn, allows for the application of the previously derived methods in Sections 3.1–3.4 to the
approximation problem.
C Proof of Theorem 3.1
Using equations (10)–(11), the objective function of (M) can be rewritten as a univariate func-
tion, denoted by F , in terms of variable b (the total BED delivered to the normal tissue by the
chemotherapeutic agent) as follows:
F (b;n) = ∆rDa (b;n) + ∆ab,
where the constant term 1
δ2
[α/β]
N
[α/β]
T
b¯ is dropped from the objective function. We consider four
possible cases based on the sign of ∆r and ∆a as follows:
(i) ∆r ≥ 0 and ∆a < 0: F (·;n) is maximized if b = 0, which corresponds to no drug
administration, that is, ci = 0 (i = 1, . . . , n). Furthermore, since ∆r ≥ 0, a standard
radiation fractionation is optimal.
(ii) ∆r < 0 and ∆a ≥ 0: F (·;n) is maximized if b = b¯, which corresponds to no radiation
administration, that is, di = 0 (i = 1, . . . , n).
(iii) ∆r < 0 and ∆a < 0: F (·;n) is a convex function if ∆r < 0 since
F ′′ (b;n) = −
2δeff∆r
nδ¯2 [α/β]N
(
1 + 4δeff
(
b¯− b
)
/nδ¯ [α/β]N
)3/2 > 0.
Therefore, maximizing F (·;n) with respect to the single variable b ∈
[
0, b¯
]
yields an optimal
solution on the boundary of the feasible region, that is, b∗ = 0 or b∗ = b¯. The boundary
solutions are
F (0;n) = ∆r
−1 +
√
1 + 4δeff b¯/nδ¯ [α/β]N
2δeff/n [α/β]N
F
(
b¯;n
)
= ∆ab¯.
Moreover, since ∆r < 0, F (·;n) is maximized if a hypo-fractionated regimen is used, that
is, n is set to the minimum number of fractions allowed n = 1. Hence, to determine the
maximum of the two values above we let
̺a =
2δeff b¯/ [α/β]N
−1 +
√
1 + 4δeff b¯/δ¯ [α/β]N
,
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so that if ∆r/∆a ≤ ̺a, then radiation alone with a hypo-fractionation scheme is optimal.
Otherwise, drug administration alone is optimal.
(iv) ∆r ≥ 0 and ∆a ≥ 0: F (·;n) is a concave function since
F ′′ (b;n) = −
2δeff∆r
nδ¯2 [α/β]N
(
1 + 4δeff
(
b¯− b
)
/nδ¯ [α/β]N
)3/2 < 0.
Moreover, it has a local maximum that can be obtained by setting F ′ (b;n) = 0, which
yields
ba = b¯+
n [α/β]N
4δ2
(
δ¯2 −
(
∆r
∆a
)2)
.
Clearly, F (·;n) is increasing for b ≤ ba and decreasing over b > ba. Thus, depending on
whether or not ba lies within the interval
[
0, b¯
]
, we can determine the global maximum of
F over
[
0, b¯
]
as follows:
b∗ =


0 ba < 0
ba 0 ≤ ba ≤ b¯
b¯ ba > b¯.
The above conditions can be expressed in terms of ∆r/∆a as follows:
b∗ =


b¯ ∆r∆a ≤ δ¯ (= ρa)
ba δ¯ ≤
∆r
∆a
≤ δ¯
√
1 + 4b¯δeff/nδ¯ [α/β]N (= ρa)
0 ∆r∆a ≥ ρa.
Therefore, the optimal regimen delivers a BED of b∗ and b¯−b∗ using the drug and radiation
administration, respectively. Finally, since ∆r ≥ 0, it is optimal to deliver radiation using
a standard fractionation scheme, that is, using maximum number of fractions allowed.
D Proof of Proposition 3.1
We show that there exists an optimal regimen
(
d∗i , c
∗
i
)
(i = 1, . . . , n) to (M) in which for any
given fractions i, i′ such that d∗i , d
∗
i′ > 0, we have d
∗
i = d
∗
i′ and c
∗
i = c
∗
i′ . To that end, we
use the Karush-Kuhn-Tucker (KKT) optimality conditions, which are necessary conditions for
local optimality if some constraint qualification is met (Bazaraa et al., 2006). In particular,
the linear-independence constraint qualification is satisfied at those solutions for which the
constraint in (2) is binding, which is the case for all optimal solutions (see Lemma 3.1). This
requires the existence of fraction i for which di > 0 since θN = 0 due to the lack of any additivity
effect. This, in turn, leads to the linear independence of gradients of active constraints in (M).
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To write the KKT conditions we associate dual multiplier ν with (2), µi (i = 1, . . . , n) with
(3), µ
i
(i = 1, . . . , n) with non-negativity constraints on the drug’s concentration in (4), and
πi (i = 1, . . . , n) with non-negativity constraints on radiation doses in (4). The KKT conditions
for (M) can then be expressed as follows:
(2)− (4)
−
(
1 + ξTci +
2di
[α/β]T
)
+ ν
(
1 + ξNci +
2δeffdi
[α/β]N
)
− πi = 0 i = 1, . . . , n (D.1)
− ξTdi + νξNdi − µi + µi = 0 i = 1, . . . , n (D.2)
ν
(
n∑
i=1
(
di +
δeffd
2
i
[α/β]N
+ ξNcidi
)
− b¯/δ¯
)
= 0 (D.3)
πidi = 0 i = 1, . . . , n (D.4)
µ
i
ci = 0 i = 1, . . . , n (D.5)
µi (c¯− ci) = 0 i = 1, . . . , n (D.6)
πi, µi, µi, ν ≥ 0 i = 1, . . . , n. (D.7)
We show that any treatment regimen that satisfies the KKT conditions above is stationary.
Consider treatment regimen (d∗i , c
∗
i ) (i = 1, . . . , n) that satisfies the KKT conditions, and sup-
pose d∗i , d
∗
i′ > 0 for fractions i and i
′. In the following, we show that d∗i = d
∗
i′ and c
∗
i = c
∗
i′ for
all possible cases:
(i) d∗i , d
∗
i′ > 0 with c
∗
i = c
∗
i′ = 0: in that case (D.4) enforces π
∗
i = π
∗
i′ = 0. Thus using (D.1)
and assuming
[α/β]
N
[α/β]
T
6= δeff we have
1 + 2d∗i / [α/β]T
1 + 2δeffd∗i / [α/β]N
=
1 + 2d∗i′/ [α/β]T
1 + 2δeffd∗i′ [α/β]N
→ d∗i = d
∗
i′ .
(ii) d∗i , d
∗
i′ > 0 with c
∗
i , c
∗
i′ = c¯: in that case, similar to the above, using (D.1) and assuming
that
[α/β]
N
[α/β]
T
6= δeff we have
1 + ξTc
∗
i + 2d
∗
i / [α/β]T
1 + ξNc∗i + 2δeffd
∗
i / [α/β]N
=
1 + ξTc
∗
i + 2d
∗
i′/ [α/β]N
1 + ξNc∗i′ + 2δeffd
∗
i′/ [α/β]N
, c∗i = c
∗
i′ = c¯→ d
∗
i = d
∗
i′ .
(iii) d∗i , d
∗
i′ > 0 with 0 < c
∗
i , c
∗
i′ < c¯: in that case (D.4), (D.5), and (D.6) enforce that π
∗
i =
π∗i′ = µ
∗
i
= µ∗
i′
= µ∗i = µ
∗
i′ = 0. Thus using (D.2) we have
(νξN − ξT) d
∗
i = (νξN − ξT) d
∗
i′ = 0→ ν =
ξT
ξN
.
Moreover, using (D.1) we have
1 + ξTc
∗
i + 2d
∗
i / [α/β]T
1 + ξNc∗i + 2δeffd
∗
i / [α/β]N
=
1 + ξTc
∗
i′ + 2d
∗
i′/ [α/β]T
1 + ξNc∗i′ + 2δeffd
∗
i′/ [α/β]N
=
ξT
ξN
→ d∗i = d
∗
i′ =
ξN − ξT
2 (δeffξT/ [α/β]N − ξN/ [α/β]T)
→ c∗i = c
∗
i′ .
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(iv) d∗i , d
∗
i′ > 0 with c
∗
i = 0 and c
∗
i′ = c¯: this solution does not satisfy the KKT conditions, and
we prove this claim by contradiction. Suppose such solution satisfies the KKT conditions,
then using (D.5) and (D.6) we have µi = µi′ = 0. Furthermore, using (D.2) we have
µ
i
= di (−ξT + νξN) , −µi′ = di′ (−ξT + νξN) .
However, µ
i
and µi′ in the above cannot simultaneously satisfy nonnegativity conditions
required by (D.7) unless ν = ξT/ξN. However, we showed in case (iii) that ν = ξT/ξN
would imply d∗i = d
∗
i′ and c
∗
i = c
∗
i′ , which is a contradiction.
(v) d∗i , d
∗
i′ > 0 with either (v-i) c
∗
i = 0 and 0 < c
∗
i′ < c¯ or (v-ii) c
∗
i = c¯ and 0 < c
∗
i′ < c¯. We prove
that neither (v-i) nor (v-ii) satisfy the KKT conditions by contradiction. We only discuss
the case of (v-i) and a similar argument applies to (v-ii). Suppose the solution satisfied the
KKT conditions, then (D.4), (D.5), and (D.6) would enforce π∗i = π
∗
i′ = µ
∗
i = µ
∗
i′
= µ∗i′ = 0.
Thus using (D.2) we have
(νξN − ξT) d
∗
i′ = 0→ ν =
ξT
ξN
.
Substituting ν in (D.1) yields
1 + 2d∗i / [α/β]T
1 + 2δeffd∗i / [α/β]N
=
1 + ξTc
∗
i′ + 2d
∗
i′/ [α/β]T
1 + ξNc∗i′ + 2δeffd
∗
i′/ [α/β]N
=
ξT
ξN
→ d∗i = d
∗
i′ =
ξN − ξT
2 (δeffξT/ [α/β]N − ξN/ [α/β]T)
→ c∗i′ = 0
which is a contradiction.
Therefore, it is shown that for all treatment regimens that satisfy the KKT conditions, if there
exist i, i′ such that d∗i , d
∗
i′ > 0, then we have d
∗
i = d
∗
i′ and c
∗
i = c
∗
i′ .
E Proof of Theorem 3.2
Considering only stationary regimens, the objective function of (M) in equation (12) can be
expressed as a univariate function, denoted by G, in terms of variable c (the stationary drug
concentration) as follows:
G (c;n) = (∆r + ξN∆sc)Ds (c;n) ,
where the constant term 1
δ2
[α/β]
N
[α/β]
T
b¯ is dropped from the objective function. G(·;n) has only a
single extremum
cs =
ρ2s − (∆r/∆s)
2
2ξN (∆r/∆s − 1)
,
which is obtained by setting G′(·;n) = 0 and thus is a unimodal function. To determine the
maximum of G(·;n) over the interval [0, c¯], we evaluate G′(·;n) at the end points of the feasible
region [0, c¯]. We consider the following four possible cases depending on the sign of ∆r and ∆s:
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(i) ∆r,∆s ≥ 0: G
′(0;n) ≥ 0 if and only if
∆r
∆s
≤
√
1 + 4δeff b¯/nδ¯ [α/β]N (= ρs),
similarly, G′ (c¯;n) ≥ 0 if and only if
∆r
∆s
≤
√
(1 + ξNc¯)
2
+ 4δeff b¯/nδ¯ [α/β]N − ξNc¯ (= ρs).
It is then easy to verify that
√
(1 + ξNc¯)
2
+ 4δeff b¯/nδ¯ [α/β]N − ξNc¯ ≤
√
1 + 4δeff b¯/nδ¯ [α/β]N. (E.1)
Based on the above, if
∆r
∆s
≤ ρ
s
,
then G(·;n) is increasing over [0, c¯] and c∗ = c¯. Next, consider the case for which G′(0;n) ≥
0 and G′ (c¯;n) ≤ 0, this corresponds to
ρ
s
≤
∆r
∆s
≤ ρs.
In this case the extremum cs ∈ [0, c¯] is a local maximum and thus the global optimal
solution. We next consider the case in which G′(0;n) ≤ 0 and G′ (c¯;n) ≥ 0. However,
this is not possible since it requires ρ
s
≥ ρs, which contradicts (E.1). Finally, we consider
G′(0;n) ≤ 0 and G′ (c¯;n) ≤ 0, which corresponds to
∆r
∆s
≥ ρs.
In this case G′(·;n) is negative and G(·;n) is decreasing over [0, c¯]. Hence, the optimal
solution is at c∗ = 0. In addition, since ∆r,∆s ≥ 0, we have ∆r + ∆sc ≥ 0 for c ∈ [0, c¯]
and thus a standard fractionation regimen is optimal.
(ii) ∆r ≤ 0 and ∆s ≥ 0: similar to case (i) G
′ (c;n) ≥ 0 for c ∈ [0, c¯] if and only if
∆r
∆s
≤
√
(1 + ξNc)
2 + 4δeff b¯/nδ¯ [α/β]N − ξNc.
This condition is met over the interval [0, c¯] because ∆r/∆s ≤ 0 and the right-hand-side
of the above inequality is always positive. Therefore, G is increasing over [0, c¯] and the
optimal solution is at c∗ = c¯. Additionally, when
∆r
∆s
< −ξNc¯,
then ∆r + ξN∆sc¯ < 0 and thus a hypo-fractionated radiation regimen is optimal. On the
contrary, when the above condition is not satisfied, then ∆r + ξN∆sc¯ ≥ 0 and a standard
fractionation regimen is optimal.
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(iii) ∆r ≤ 0 and ∆s ≤ 0: G
′(0;n) ≥ 0 if and only if
∆r
∆s
≥ ρs,
and G′ (c¯;n) ≥ 0 if and only if
∆r
∆s
≥ ρ
s
.
Therefore, it is not possible to have G′(0;n) ≥ 0 and G′(c¯;n) ≤ 0 since in that case we
would have ρ
s
≥ ρs, which is in contradiction with inequality (E.1). Thus, there is no local
maximum within the interval (0, c¯) and the optimal solution must lie on the boundary of
[0, c¯], that is, c∗ = 0 or c∗ = c¯. More specifically, the global maximum is
G∗ = max
{
G(0;n), G(c¯;n)
}
= max
{
∆rDs (0;n) , (∆r + ξN∆sc¯)Ds (c¯;n)
}
,
which can be determined using the following condition: if
∆r
∆s
≤
ξNc¯
Ds (0;n) /Ds (c¯;n)− 1
(= ̺s),
then c∗ = 0; otherwise, c∗ = c¯. Finally, since ∆r+ξN∆sc ≤ 0 for c ≥ 0, a hypo-fractionated
radiation regimen is always optimal, that is, n = 1.
(iv) ∆r ≥ 0 and ∆s ≤ 0: for any given c ∈ [0, c¯] we have G
′ (c;n) ≥ 0 if and only if
∆r
∆s
≥
√
(1 + ξNc)
2 + 4δeff b¯/nδ¯ [α/β]N − ξNc ∀c ∈ [0, c¯] .
However, since ∆r/∆s ≤ 0 and the right-hand-side of the above inequality is positive, the
above condition cannot be satisfied and G′ (c;n) ≤ 0 for c ∈ [0, c¯]. Therefore, G (c;n) is
decreasing over the interval [0, c¯] and c∗ = 0 is the global maximum. Moreover, at c = 0,
∆r + ξN∆sc = ∆r > 0 and thus a standard fractionation regimen is optimal.
F Trade-off between target and normal-tissue BED
The second derivative of H with respect to b is
H ′′ (b;n) =
−2δeff∆r
[α/β]N δ¯
2
(
1 + 4δeffb/nδ¯ [α/β]N
)3/2 .
Therefore, it is easy to see that H is convex when ∆r < 0 and concave otherwise.
39
